In a new @nytimes.com op-ed, immunologist Elisabeth Marnik, PhD, reflects on growing up unvaccinated and explains why empathy, not shame, is key to addressing vaccine hesitancy. bit.ly/3MBIbc5
27.02.2026 15:51 —
👍 1
🔁 1
💬 0
📌 0
Congrats to @drtoddlee.bsky.social & @dremilymcd.bsky.social on conducting this and getting it out there for us. Look forward to wading through the details soon!
27.02.2026 16:57 —
👍 8
🔁 1
💬 0
📌 0
That's how I interpret this. Might help some patients in the hospital who are severely ill get through their initial episode without a recurrence for awhile longer, but not sure how much this helps my stable outpatient who is either going to recur or not recur no matter how much PO vanc I give them
27.02.2026 16:52 —
👍 10
🔁 0
💬 1
📌 0
General ID team powering through Friday rounds!
#SelfiesonService @drjrmarcelin.bsky.social
27.02.2026 16:46 —
👍 2
🔁 1
💬 0
📌 0
#IDsky sharing one of the Stanford's ID fellow's meded site infectiousdiseasehub.com #idmeded #meded
26.02.2026 00:33 —
👍 2
🔁 2
💬 0
📌 0
Tecovirimat for the Treatment of Mpox | NEJM
Tecovirimat is approved for smallpox treatment under the Food and Drug Administration
Animal Rule on the basis of efficacy in nonhuman primate models of mpox (previously
known as monkeypox). Howeve...
The STOMP/A5418 Trial is out:
- Clinical Resolution: 83% tecovirimat, 84% placebo
- No significant differences in pain, time to lesion healing, or viral DNA clearance
- Similar results to PALM007 for clade 1 MPXV
*Tecovirimat seems to lack efficacy in clade I and II
www.nejm.org/doi/full/10....
25.02.2026 23:25 —
👍 2
🔁 1
💬 0
📌 0
The summary page of the WikiGuidelines endocarditis section on nutritionally variant streptococci
The @wiki-guidelines.bsky.social endocarditis guidelines are awesome, but very special thank you to the folks in charge of the nutritionally variant streptococci section.
This page was so useful this week in informing treatment choices 😇🥰
@bradspellberg.bsky.social thanks to y’all!
#IDSky #MedSky
25.02.2026 23:17 —
👍 8
🔁 1
💬 0
📌 0
Emergence of dalbavancin, vancomycin, and daptomycin cross-resistance in MRSA during long-term LVAD suppression with vancomycin followed by dalbavancin: genomic insights and synergy with cefadroxil
✅ Just Accepted
🔗 https://bit.ly/4azpqPJ
24.02.2026 21:55 —
👍 8
🔁 3
💬 0
📌 4
@marinschweizer.bsky.social: Among younger, immunocompetent patients who underwent debridement, antibiotics, and implant retention for PJI, receipt of suppressive antibiotic therapy was associated with ⬇️ death or treatment failure but also associated with side effects. doi.org/10.1017/ash....
24.02.2026 20:30 —
👍 2
🔁 1
💬 1
📌 0
Really enjoyed this episode, especially the parts on plague doctors (admittedly I dressed up as one this Halloween!)
24.02.2026 18:23 —
👍 1
🔁 0
💬 1
📌 0
Yes second of these studies. Historically the dose was set roughly like this:
1) Establish MIC in the rabbit
2) WHO group said well for humans lets go 6-10* higher than that for safety
3) And for late syphilis lets go three times dosing too
Ripe for a proper trial.
23.02.2026 19:27 —
👍 4
🔁 1
💬 1
📌 0
Wow. Had no idea where that dosing came from. So many rabbit models in ID determining doses and durations. I was happy to see this coming from CDC. Hope they can spur funding for a trial. Could be huge during PenG shortage and for stewardship
23.02.2026 19:35 —
👍 2
🔁 0
💬 0
📌 0
Associations between suppressive antibiotic therapy, treatment failure, and side effects among young, immunocompetent veterans with prosthetic joint infection who undergo debridement, antibiotics, and implant retention
View
abstract
Objective:Suppressive antibiotic therapy (SAT) is used to prevent recurrent prosthetic joint infections (PJI) among patients who undergo debridement, antibiotics, and implant retention (DAIR). We aimed to assess SAT outcomes among younger, immunocompetent patients.Design:Retrospective cohort study.Patients:Immunocompetent patients <65 years of age who received DAIR for PJI of the hip, knee, or shoulder.Setting:Veterans Affairs hospitals.Methods:SAT was divided into short-term (oral antibiotics given for <3 months after guideline concordant therapy) and long-term SAT (>3 months to 5 years of oral antibiotics). The primary outcome was treatment failure (TF) and mortality combined. SAT was a time-dependent covariate in Cox proportional hazards models.Results:Of the 938 patients, 15% received short-term SAT, 20% received long-term SAT, and 65% did not receive SAT. Short- and long-term SAT were significantly associated with decreased hazards of TF or mortality (short-term SAT adjusted hazard ratio (aHR) = 0.27; 95% confidence interval (CI): 0.11, 0.67; Long-term SAT aHR = 0.52; 95% CI: 0.30, 0.89). Short-term SAT was significantly associated with C. difficile infection (aHR: 3.47; 95% CI: 1.38, 8.74). Short-term SAT (aHR: 7.83; 95% CI: 4.80, 12.77) and long-term SAT (aHR: 1.68; 95% CI: 1.19, 2.38) were significantly associated with antibiotic-associated diarrhea. Long-term SAT was not significantly associated with TF alone (aHR = 0.61; 95% CI: 0.32, 1.16).Conclusions:SAT was significantly associated with decreased death or TF and increased side effects. Benefits and risks must be weighed before prescribing SAT to younger, immunocompetent patients.
SAT in <65 immunocompetent PJI pts ↓ death/TF: short-term aHR 0.27, long-term 0.52. Short-term ↑ C.diff (aHR 3.47) & diarrhea (aHR 7.83). Balance benefits/risks⚖️
23.02.2026 13:30 —
👍 1
🔁 1
💬 0
📌 0
Is one dose of PenG or 28-days doxycycline adequate for late/unknown syphilis? This study is encouraging! @drmichaelmarks.bsky.social
23.02.2026 18:13 —
👍 8
🔁 1
💬 1
📌 0
Disconcerting to see such low performance of Legionella urine Ag in a sick population.
Reinforces my strategy that if a patient is sick enough, may not discontinue Legionella coverage just for a negative urine antigen.
22.02.2026 20:34 —
👍 5
🔁 1
💬 1
📌 0
I was always taught the urine antigen had a sensitivity of 70%. Of course, I’m not sure the gold standard for that (if it’s culture, which is insensitive, then antigen is even less sensitive). May depend a bit on which Legionella species are in a locale too
22.02.2026 21:00 —
👍 2
🔁 0
💬 0
📌 0
In this interim analysis, there is NO increased safety risk associated with #RSV vaccination in pregnant women: preterm birth, PROM, preterm PROM, & HTNsive disorders of pregnancy #IDSky #MedSky #VaccinesWork jamanetwork.com/journals/jam...
20.02.2026 00:34 —
👍 6
🔁 3
💬 0
📌 0
In this 3rd collaboration between SIDP Breakpoints & ESCMID’s Communicable, Erin McCreary, PharmD & Angela Huttner host Pranita Tamma (USA) & Benedikt Huttner (WHO, Switzerland) to discuss #guidelines & guidance, offering a behind-the-scenes look into their development, reach - and limits.
#IDSky
19.02.2026 10:00 —
👍 6
🔁 2
💬 0
📌 0
Congratulations to CID’s 2025 reviewers of the year!
-Nicolás Cortés-Penfield, MD, FACP, FIDSA
-Esteban Martinez, MD, PhD
-Jose F. Portugal Gonzales, MD
Learn more about how you can receive recognition and rewards as a peer reviewer: https://bit.ly/4aoKJ6S
17.02.2026 22:40 —
👍 12
🔁 4
💬 0
📌 0
